LATEST ADVANCES IN INJECTABLE AND ORAL MEDICATIONS FOR TYPE 2 DIABETES TREATMENT
Abstract
Introduction: Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and impaired beta-cell function. Effective management extends beyond glycemic control and includes weight reduction and cardiovascular risk mitigation. In recent years, injectable therapies such as GLP-1 receptor agonists and the novel dual GIP/GLP-1 receptor agonist tirzepatide have shown promising results. These agents offer significant improvements in blood glucose levels, body weight, and cardiometabolic outcomes, positioning them as essential components of modern T2DM treatment strategies.
Materials and Methods: This article presents a comprehensive review of literature derived from the PubMed database, encompassing studies published between 2015 and 2025.
Results: Recent clinical studies confirm the effectiveness of GLP-1 receptor agonists (GLP-1RAs) and the dual GIP/GLP-1 agonist tirzepatide in managing type 2 diabetes. Long-acting GLP-1RAs, especially semaglutide, show superior HbA1c and weight reduction compared to other agents. Tirzepatide demonstrated even greater efficacy than semaglutide in reducing blood glucose and body weight, along with benefits for blood pressure and lipid levels. Both drugs have similar safety profiles, with mild gastrointestinal side effects. The development of oral semaglutide further enhances treatment options, particularly for patients avoiding injections.
Conclusions: Advances in injectable therapies for type 2 diabetes, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide, have significantly improved glycemic control, weight management, and cardiovascular outcomes. Tirzepatide shows greater efficacy than semaglutide in reducing HbA1c and body weight. While safety profiles are favorable, long-term data are still needed. These therapies offer personalized treatment options, supporting better long-term health for people with type 2 diabetes.
References
Malik A, Ahmed M, Mansoor S, Ambreen S, Usman B, Shehryar M. Cognitive Impairment in Type 2 Diabetes Mellitus. Cureus. 2022 Feb 14;14(2):e22193. doi: 10.7759/cureus.22193. Erratum in: Cureus. 2022 Mar 18;14(3):c59. doi: 10.7759/cureus.c59. PMID: 35308758; PMCID: PMC8925983.
Młynarska E, Czarnik W, Dzieża N, Jędraszak W, Majchrowicz G, Prusinowski F, Stabrawa M, Rysz J, Franczyk B. Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. Int J Mol Sci. 2025 Jan 27;26(3):1094. doi: 10.3390/ijms26031094. PMID: 39940862; PMCID: PMC11817707.
Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein H, Müller-Wieland D, Nauck MA, Reuter HM, Siegel E. Therapy of Type 2 Diabetes. Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S73-S92. doi: 10.1055/a-1018-9106. Epub 2019 Dec 20. PMID: 31860927.
Zhao M, Sun S, Huang Z, Wang T, Tang H. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):70-78. doi: 10.2215/CJN.11220720. Epub 2020 Dec 29. PMID: 33376101; PMCID: PMC7792639.
Iwasaki H, Yagyu H, Shimano H. A Comprehensive Analysis of Diabetic Complications and Advances in Management Strategies. J Atheroscler Thromb. 2025 May 1;32(5):550-559. doi: 10.5551/jat.65551. Epub 2025 Jan 10. PMID: 39805627; PMCID: PMC12055507.
Javeed N, Matveyenko AV. Circadian Etiology of Type 2 Diabetes Mellitus. Physiology (Bethesda). 2018 Mar 1;33(2):138-150. doi: 10.1152/physiol.00003.2018. PMID: 29412061; PMCID: PMC5899235.
Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther. 2024 Oct 2;9(1):262. doi: 10.1038/s41392-024-01951-9. PMID: 39353925; PMCID: PMC11445387.
Ismail L, Materwala H, Al Kaabi J. Association of risk factors with type 2 diabetes: A systematic review. Comput Struct Biotechnol J. 2021 Mar 10;19:1759-1785. doi: 10.1016/j.csbj.2021.03.003. PMID: 33897980; PMCID: PMC8050730.
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275. doi: 10.3390/ijms21176275. PMID: 32872570; PMCID: PMC7503727.
Zhang Y, Pan XF, Chen J, Xia L, Cao A, Zhang Y, Wang J, Li H, Yang K, Guo K, He M, Pan A. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia. 2020 Jan;63(1):21-33. doi: 10.1007/s00125-019-04985-9. Epub 2019 Sep 4. PMID: 31482198.
Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019 Aug 29;55(9):546. doi: 10.3390/medicina55090546. PMID: 31470636; PMCID: PMC6780236.
Chandrasekaran P, Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int J Mol Sci. 2024 Feb 4;25(3):1882. doi: 10.3390/ijms25031882. PMID: 38339160; PMCID: PMC10855901.
Cloostermans L, Wendel-Vos W, Doornbos G, Howard B, Craig CL, Kivimäki M, Tabak AG, Jefferis BJ, Ronkainen K, Brown WJ, Picavet SH, Ben-Shlomo Y, Laukkanen JA, Kauhanen J, Bemelmans WJ. Independent and combined effects of physical activity and body mass index on the development of Type 2 Diabetes - a meta-analysis of 9 prospective cohort studies. Int J Behav Nutr Phys Act. 2015 Dec 1;12:147. doi: 10.1186/s12966-015-0304-3. PMID: 26619831; PMCID: PMC4666059.
Debnath DJ, Ray J, Jah SM, Marimuthu Y. Smoking and the Risk of Type 2 Diabetes: A Cross-sectional Analytical Study. Indian J Community Med. 2024 Jul-Aug;49(4):588-592. doi: 10.4103/ijcm.ijcm_1009_22. Epub 2024 Jul 9. PMID: 39291121; PMCID: PMC11404421.
Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Transl Res. 2017 Jun;184:101-107. doi: 10.1016/j.trsl.2017.02.004. Epub 2017 Mar 6. PMID: 28336465; PMCID: PMC5429867.
Rouland A, Thuillier P, Al-Salameh A, Benzerouk F, Bahougne T, Tramunt B, Berlin I, Clair C, Thomas D, Le Faou AL, Vergès B, Durlach V. Smoking and diabetes. Ann Endocrinol (Paris). 2024 Dec;85(6):614-622. doi: 10.1016/j.ando.2024.08.001. Epub 2024 Aug 30. PMID: 39218351.
Knott C, Bell S, Britton A. Alcohol Consumption and the Risk of Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of More Than 1.9 Million Individuals From 38 Observational Studies. Diabetes Care. 2015 Sep;38(9):1804-12. doi: 10.2337/dc15-0710. PMID: 26294775.
Chong K, Chang JK, Chuang LM. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J Med Sci. 2024 Mar;40(3):212-220. doi: 10.1002/kjm2.12800. Epub 2024 Jan 6. PMID: 38183334; PMCID: PMC11895656.
Thrasher J. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004. PMID: 28526182.
Majety P, Lozada Orquera FA, Edem D, Hamdy O. Pharmacological approaches to the prevention of type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023 Mar 9;14:1118848. doi: 10.3389/fendo.2023.1118848. PMID: 36967777; PMCID: PMC10033948.
Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021 Jan 19;131(2):e142243. doi: 10.1172/JCI142243. PMID: 33463546; PMCID: PMC7810496.
Blahova J, Martiniakova M, Babikova M, Kovacova V, Mondockova V, Omelka R. Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus. Pharmaceuticals (Basel). 2021 Aug 17;14(8):806. doi: 10.3390/ph14080806. PMID: 34451903; PMCID: PMC8398612.
Rao S. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9. PMID: 34881413; PMCID: PMC8866261.
Moradi-Marjaneh R, Paseban M, Sahebkar A. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes. Phytother Res. 2019 Oct;33(10):2518-2530. doi: 10.1002/ptr.6421. Epub 2019 Jul 29. PMID: 31359514.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14. PMID: 33068776; PMCID: PMC8085572.
Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation. 2022 Dec 13;146(24):1882-1894. doi: 10.1161/CIRCULATIONAHA.122.059595. Epub 2022 Dec 12. PMID: 36508493.
Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136. PMID: 28847797.
Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022 Oct;23(5):979-994. doi: 10.1007/s11154-022-09735-8. Epub 2022 Jul 15. PMID: 35838946; PMCID: PMC9515042.
Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne). 2020 Apr 3;11:178. doi: 10.3389/fendo.2020.00178. PMID: 32308645; PMCID: PMC7145895.
Makrilakis K. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect. Int J Environ Res Public Health. 2019 Jul 30;16(15):2720. doi: 10.3390/ijerph16152720. PMID: 31366085; PMCID: PMC6696077.
Razavi M, Wei YY, Rao XQ, Zhong JX. DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Mil Med Res. 2022 Aug 20;9(1):45. doi: 10.1186/s40779-022-00410-2. PMID: 35986429; PMCID: PMC9392232.
Carr RD, Solomon A. Inhibitors of dipeptidyl peptidase-4 as therapeutic agents for individuals with type 2 diabetes: a 25-year journey. Diabet Med. 2020 Aug;37(8):1230-1233. doi: 10.1111/dme.14325. Epub 2020 Jun 8. PMID: 32426859; PMCID: PMC7496331.
Sardar MB, Nadeem ZA, Babar M. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024 May;49(5):102489. doi: 10.1016/j.cpcardiol.2024.102489. Epub 2024 Feb 28. PMID: 38417475.
Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020 Sep 3;5(17):e140532. doi: 10.1172/jci.insight.140532. PMID: 32730231; PMCID: PMC7526454.
De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes Metab. 2023 Jan;25(1):3-17. doi: 10.1111/dom.14831. Epub 2022 Aug 31. PMID: 35929488; PMCID: PMC10087310.
Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004. doi: 10.2337/dc22-1710. PMID: 36857477; PMCID: PMC10154650.
Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025 Jan;26(1):31-49. doi: 10.1080/14656566.2024.2436595. Epub 2024 Dec 4. PMID: 39632534.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024 Sep 1;184(9):1056-1064. doi: 10.1001/jamainternmed.2024.2525. PMID: 38976257; PMCID: PMC11231910.
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Erratum in: Lancet. 2021 Jul 17;398(10296):212. doi: 10.1016/S0140-6736(21)01556-7. PMID: 34186022.
Views:
23
Downloads:
8
Copyright (c) 2025 Katarzyna Jurkiewicz, Marek Ciechański, Aleksandra Kasprzyk, Klaudia Wilk, Edyta Witkowska, Szymon Cholewiński, Bernadetta Wilk, Piotr Stachura, Piotr Rejman, Katarzyna Pszczoła
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
